Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy is the most common inherited neuromuscular disorder that affects all races and ethnicities. Affecting only males, it occurs in 1/3,600 live-born infant boys and some affected newborns may have some mild hypotonia, other symptoms are rarely present at birth or in early infancy. The disease is caused by mutations in Duchenne muscular dystrophy (DMD) (encodingdystrophin) that abolish the production of dystrophin in muscle.

“Duchenne Muscular Dystrophy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Duchenne Muscular Dystrophy Market. 

The Duchenne Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Duchenne Muscular Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Duchenne Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Duchenne Muscular Dystrophy Key players such as – Vertex Pharmaceuticals, Bioleaders Corporation, Mitobridge, Daiichi Sankyo, Sarepta Therapeutics, Capricor, Sarepta Therapeutics, Taiho Pharmaceutical, FibroGen, Santhera Pharmaceuticals, Italfarmaco, Wave Life Sciences Ltd., EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others, are developing therapies for the Duchenne Muscular Dystrophy treatment 

• Duchenne Muscular Dystrophy Emerging therapies such as – CRISPR/Cas9 gene editing therapy, BLS-M22, MA-0211, DS-5141, SRP-5051, CAP 1002, SRP-9001, TAS-205, Pamrevluma, and others are expected to have a significant impact on the Duchenne Muscular Dystrophy market in the coming years.   
• In April 2019, U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD)
• In December 2020, Fibrogen started A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab or Placebo in combination with systemic corticosteroids in ambulatory subjects with Duchenne muscular Dystrophy (DMD) 

Duchenne Muscular Dystrophy Pipeline Therapeutics Assessment

• Duchenne Muscular Dystrophy Assessment by Product Type
• Duchenne Muscular Dystrophy By Stage and Product Type
• Duchenne Muscular Dystrophy Assessment by Route of Administration
• Duchenne Muscular Dystrophy By Stage and Route of Administration
• Duchenne Muscular Dystrophy Assessment by Molecule Type
• Duchenne Muscular Dystrophy by Stage and Molecule Type 

DelveInsight’s Duchenne Muscular Dystrophy Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Duchenne Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:

• CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals
• BLS-M22: Bioleaders Corporation
• MA-0211: Mitobridge
• DS-5141: Daiichi Sankyo
• SRP-5051: Sarepta Therapeutics
• CAP 1002: Capricor
• SRP-9001: Sarepta Therapeutics
• TAS-205: Taiho Pharmaceutical
• Pamrevlumab: FibroGen 

Duchenne Muscular Dystrophy Pipeline Analysis:

The Duchenne Muscular Dystrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Duchenne Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy Treatment.
• Duchenne Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Duchenne Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Duchenne Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Duchenne Muscular Dystrophy product details are provided in the report. Download the Duchenne Muscular Dystrophy pipeline report to learn more about the emerging Duchenne Muscular Dystrophy therapies

Duchenne Muscular Dystrophy Pipeline Market Drivers

• Robust Duchenne Muscular Dystrophy pipeline
• Development of Mutation Suppression therapies

Duchenne Muscular Dystrophy Pipeline Market Barriers

• High cost of Duchenne Muscular Dystrophy treatments
• Regulatory procedure & and lack of standardized protocol

Get a Free Sample PDF Report to know more about Duchenne Muscular Dystrophy Pipeline Assessment

Scope of Duchenne Muscular Dystrophy Pipeline Drug Insight    

• Coverage: Global
• Key Duchenne Muscular Dystrophy Companies: Vertex Pharmaceuticals, Bioleaders Corporation, Mitobridge, Daiichi Sankyo, Sarepta Therapeutics, Capricor, Sarepta Therapeutics, Taiho Pharmaceutical, FibroGen, Santhera Pharmaceuticals, Italfarmaco, Wave Life Sciences Ltd., EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others
• Key Duchenne Muscular Dystrophy Therapies: CRISPR/Cas9 gene editing therapy, BLS-M22, MA-0211, DS-5141, SRP-5051, CAP 1002, SRP-9001, TAS-205, Pamrevluma, and others
• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
• Duchenne Muscular Dystrophy Market Dynamics:  Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers 

Request for Sample PDF Report for Duchenne Muscular Dystrophy Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Duchenne Muscular Dystrophy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com